DeepMed Research

Alaunos Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Employees: 1

Market Cap: $4.4M

Website: http://www.alaunos.com

Introduction: ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Clinical Trials

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Active, not recruiting

Conditions: Colorectal Cancer
Pancreatic Cancer
Non-small Cell Lung Cancer
Ovarian Cancer
Adenocarcinoma of Lung
Adenosquamous Cell Lung Cancer
Ovary Neoplasm
Cholangiocarcinoma
Gynecologic Cancer
Squamous Cell Lung Cancer

Interventions: Biological: Neoantigen specific TCR-T cell drug product

First Posted Date: 2022-03-23

Last Posted Date: 2024-05-29

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 8

Registration Number: NCT05292859

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Ovary Neoplasm
Adenosquamous Cell Lung Cancer
Cholangiocarcinoma
Adenocarcinoma of Lung
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Endometrial Cancer
Non-small Cell Lung Cancer
Ovarian Carcinoma

Interventions: Biological: Neoantigen specific TCR-T cell drug product
Biological: Aldesleukin (IL-2)

First Posted Date: 2022-01-18

Last Posted Date: 2024-05-29

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 180

Registration Number: NCT05194735

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Suspended

Conditions: Colo-rectal Cancer
Endometrial Cancer
Pancreas Cancer
Ovarian Cancer
Cholangiocarcinoma
Non-small Cell Lung Cancer

First Posted Date: 2021-11-18

Last Posted Date: 2024-05-29

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 2000

Registration Number: NCT05124743

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Phase 2

Terminated

Conditions: Glioblastoma

Interventions: Biological: Ad-RTS-hIL-12
Drug: Veledimex
Drug: Cemiplimab-Rwlc

First Posted Date: 2019-07-02

Last Posted Date: 2025-04-18

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 40

Registration Number: NCT04006119

Locations: 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸
Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸
University of California - San Francisco, San Francisco, California, United States

and more 4 locations

Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Biological: Ad-RTS-hIL-12
Drug: veledimex

First Posted Date: 2018-09-20

Last Posted Date: 2021-09-22

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 36

Registration Number: NCT03679754

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
NYU - Langone Health, New York, New York, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 1 locations

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Biological: Ad-RTS-hIL-12
Drug: veledimex
Drug: Nivolumab

First Posted Date: 2018-08-17

Last Posted Date: 2021-10-04

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 21

Registration Number: NCT03636477

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 1 locations

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Phase 1

Terminated

Conditions: Pediatric Brain Tumor
Diffuse Intrinsic Pontine Glioma

Interventions: Biological: Ad-RTS-hIL-12
Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
Drug: Oral Veledimex - Arm 2 (DIPG)

First Posted Date: 2017-11-06

Last Posted Date: 2021-11-11

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 6

Registration Number: NCT03330197

Locations: 🇺🇸
Dana- Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California San Francisco, Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: Ad-RTS-hIL-12
Drug: Veledimex

First Posted Date: 2015-04-22

Last Posted Date: 2021-10-08

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 9

Registration Number: NCT02423902

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Anaplastic Oligoastrocytoma

Interventions: Biological: Ad-RTS-hIL-12
Drug: veledimex

First Posted Date: 2014-01-01

Last Posted Date: 2025-04-16

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 40

Registration Number: NCT02026271

Locations: 🇺🇸
Cedars-Sinai, Los Angeles, California, United States
🇺🇸
University of California - San Francisco, San Francisco, California, United States
🇺🇸
Northwestern, Chicago, Illinois, United States

and more 3 locations

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer Nos Metastatic Recurrent

Interventions: Genetic: Ad-RTS-hIL-12 and Veledimex
Drug: Palifosfamide

First Posted Date: 2012-10-10

Last Posted Date: 2015-01-27

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 12

Registration Number: NCT01703754

Locations: 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸
Signal Point Clinical Research Center, Middletown, Ohio, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy